Make it stop. For life. in Quebec with a strong IBD community!

Here in Quebec, we are home to a strong community of volunteers, donors and sponsors, as well as an innovative team of researchers and health professionals. These people are the heart and soul of our organization, and there are so many exciting ways to get involved! Every volunteer, donor, researcher and sponsor helps us to improve the lives of those affected by Crohn’s disease and ulcerative colitis, and brings us closer to finding cures.

We welcome newcomers – contact us today and, together, we’ll make it stop. For life.

For general and in-memory donations, please call 514-342-0666 ext. 201
For French inquiries, please call 514-342-0666 ext. 202


Katherine Digby
Regional Director, Quebec & Atlantic Provinces
kdigby@crohnsandcolitis.ca

Development Coordinator, Montreal​
DC-Mtl@crohnsandcolitis.ca​
514-342-0666  ext. 201

Development Coordinator, Quebec​
DC-Qc@crohnsandcolitis.ca​
514-342-0666  ext. 202

Slashing Crohn's participants

The 7th Annual Slashing Crohn's and Colitis

Le Rinque, Crohn's and Colitis Canada and Generation C presentsTHE 7TH ANNUAL SLASHING CROHN'S AND COLITIS 2 DAY BALL HOCKEY TOURNAMENTSupport Generation C by either donating to a team or by ...

 • 
Le Rinque, 8355 Ch. Montview, Ville Mont-Royal H4P 2L9
Montreal
 • 
Remember to bookmark this page.

PROVINCE OF QUEBEC’S OFFICE

5530 Rue Ferrier
Mont-Royal, QC H4P 1M2

kdigby@crohnsandcolitis.ca 514-342-0666 ext. 200 1-800-461-4683 (Québec and NB only)

Search by Postal Code

News

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

The Canadian Inflammatory Bowel Disease Research Consortium awards first $1M Pioneer Grant from Takeda Canada

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Crohn’s and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease

 1 2 3 4 5 6 7 8 9 10